Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Multicenter Observational Study Reveals No Impact of Biologic and Targeted Synthetic DMARDs on Bone Loss in Rheumatoid Arthritis Patients

  • By

  • Takafumi Aritomi

  • Koshiro Sonomoto

  • Shingo Nakayamada

  • Hiroaki Tanaka

  • Atsushi Nagayasu

  • Satoshi Kubo

  • Ippei Miyagawa

  • Ayako Yamaguchi

  • Naoaki Ohkubo

  • Yasuyuki Todoroki

  • Yurie Satoh-Kanda

  • Masanobu Ueno

  • Ryuichiro Kanda

  • Yuya Fujita

  • Masashi Funada

  • Hidenori Sakai

  • Satsuki Matsunaga

  • Masayuki Shinojima

  • Hiroki Kawamura

  • Kazuki Takahashi

  • Miyabi Ando

  • Kazuki Haru

  • Yusuke Miyazaki

  • Kentaro Hanami

  • Masao Nawata

  • Shunsuke Fukuyo

  • Keisuke Nakatsuka

  • Mikiko Tokunaga

  • Kazuyoshi Saito

  • Yoshiya Tanaka

  • April 21, 2026

Share

  • 1

    Rheumatoid arthritis is associated with systemic osteoporosis, which is prevalent and often untreated among patients, especially those using glucocorticoids.

  • 2

    Biologic and targeted synthetic DMARDs effectively control arthritis but may not improve systemic bone loss in rheumatoid arthritis patients.

  • 3

    A recent study involving 1,164 RA patients showed significant decreases in bone mineral density despite treatment with b/tsDMARDs.

  • 4

    The study emphasizes the need for ongoing attention to osteoporosis management in RA, as treatment rates remain low.

  • 5

    Long-term outcomes of b/tsDMARDs on bone metabolism in RA patients are still uncertain, necessitating further investigation.

Original Source(s)

Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study

  • by Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh-Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka

  • April 21, 2026

Related Content

Serostatus May Modify RA Activity–CV Link

Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.

GLP-1 RAs May Ease Psoriasis, PsA Data Limited

Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.

Gout and allopurinol adherence in newly diagnosed patients and the risk of fractures: a nationwide cohort study